AVROBIO INC. overview

CAMBRIDGE, Mass., Feb. 01, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced a time change for its analyst and investor presentation and webcast scheduled for Wednesday, February 6, 2019, at which time the Company will provide clinical trial updates related to its investigational gene therapy program for AVR-RD-01 in Fabry disease. The Company’s presentation and webcast is now scheduled to start at 5:30...

CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”) a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene therapy candidate for cystinosis , AVR-RD-04, is cleared to begin a Phase 1/2 clinical trial, following acceptance of the investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). The Phase 1/2 clinical trial is a planned investigator-sponsored trial to be conducted by...

CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that clinical trial updates related to the Company’s gene therapy program for AVR-RD-01 in Fabry disease will be presented at WORLD Symposium , an annual conference dedicated to lysosomal diseases, being held February 4-8, 2019 in Orlando, Florida. AVROBIO will host an event for analysts and investors in conjunction with the...

CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”), a clinical-stage gene therapy company, today announced the appointment of Philip J. Vickers, Ph.D., to its Board of Directors. Dr. Vickers brings a wealth of global pharmaceutical and biotechnology expertise to AVROBIO, with more than 25 years’ experience in the development and approval of innovative biologics and small molecules to treat diseases in a wide range of therapeutic areas. The...

CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI). AVROBIO’s addition to the NBI will become effective prior to market open on Monday, December 24, 2018. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market®...

CAMBRIDGE, Mass., Dec. 19, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-01, for the treatment of Fabry disease. The gene therapy consists of the patient’s own hematopoietic stem cells...

CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced the grant of non-qualified stock options to purchase 293,000 shares of common stock, effective on December 17, 2018. Such options were previously approved by the Compensation Committee, as a material inducement to the employment of Dr. Birgitte Volck, M.D., Ph.D., the Company’s new President of Research and Development. The equity...